Invitation to Roche ’s Virtual Pipeline Event from WFH 2018 World Congress
We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Wednesday, 23 May 2018, from the World Federation of Hemophilia (WFH) 2018 World Congress (20-24 May 2018) in Glasgow, Scotland. (Source: Roche Investor Update)
Source: Roche Investor Update - May 11, 2018 Category: Pharmaceuticals Source Type: news

Single injection treats hemophilia B for life, in proof-of-concept study
(Salk Institute) Salk researchers have demonstrated in mice that hemophilia B can be treated for life with one single injection containing disease-free liver cells that can produce their missing clotting factor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news

Blood scandal victims need more cash, says Haemophilia Wales
There are calls for Welsh infected blood scandal victims to get the same payments as those in Scotland. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - April 26, 2018 Category: Consumer Health News Source Type: news

Kenya:One in 10,000 Kenyans Has Haemophilia, Says Report
[Nation] Kenya joined other countries in marking the World Haemophilia Day on Tuesday. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 18, 2018 Category: African Health Source Type: news

Mauritius:Signing of Medical Twinning With South Africa in the Field of Hemophilia
[Government of Mauritius] The Jawaharlal Nehru Hospital and the Charlotte Maxeke Johannesburg Academic Hospital of South Africa signed yesterday a medical twinning in the field of hemophilia at the Victoria Hospital in Candos. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 17, 2018 Category: African Health Source Type: news

FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. Breakthrough Therapy Designation is designed to accelerate the development and review of medicines intended to treat a serious condition with preliminary evidence that indicates they may demonstrate a substantial improvement over existing therapies. (Source: World Pharma News)
Source: World Pharma News - April 17, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Britain ’s use of contaminated blood was no ‘tragedy’ – it was a scandal | Simon Hattenstone
The latest inquiry must discover how thousands of haemophiliacs contracted HIV or hepatitis C from blood products, and why it was covered up for so longIn two weeks ’ time Sir Brian Langstaff will take up his post as chair of thepublic inquiry into contaminated blood and contaminated blood products. Today, World Haemophilia Day, is the perfect occasion to remind Langstaff what the thousands of haemophiliac victims need from this inquiry if they are to get justice.In the 1970s and 1980s more than 4,600 haemophiliacs contracted HIV or hepatitis C after being infected by contaminated blood-clotting products. Much of the...
Source: Guardian Unlimited Science - April 17, 2018 Category: Science Authors: Simon Hattenstone Tags: Health Society Hepatitis B Hepatitis C Aids and HIV NHS Health policy Politics UK news Science Medical research Source Type: news

Roche's Hemlibra gets speedy FDA review for wider use
ZURICH (Reuters) - Roche's hemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company's plans to muscle in on turf dominated by rivals including Shire. (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Hemlibra in haemophilia A without inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra ® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - April 17, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Hemlibra in haemophilia A without inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra ® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - April 17, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Hemlibra in haemophilia A without inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra ® (emicizumab-kxwh) for people with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - April 17, 2018 Category: Pharmaceuticals Source Type: news

FDA Grants Breakthrough Therapy Designation For Genentech ’s Hemlibra (emicizumab-kxwh) in Hemophilia A Without Inhibitors
South San Francisco, CA -- April 16, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Hemlibra... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - April 16, 2018 Category: Drugs & Pharmacology Source Type: news

Patient Support Program Triumphs
A patient support program offering around the clock assistance to glioblastoma multiforme (GBM) patients undergoing an innovative therapy has been named the Most Valuable Patient Initiative award at eyeforpharma ’s annual awards ceremony in Philadelphia.   Reflecting on the win, Novocure said: “We are humbled to have helped so many patients and to be recognised for it by our peers who have made careers out of trying to help patients in the most need. The eyeforpharma awards are helping pharma to focus on its core constituent — the patient.”  In naming the PSP as the winner of the 2018...
Source: EyeForPharma - April 10, 2018 Category: Pharmaceuticals Authors: Adam Chapman Source Type: news

Helping Patients Learn Healthy Habits
What if we told you we could improve health outcomes for more than 50% of patients and save the US healthcare system up to $289bn a year?That ’s the averagecost of nonadherence to prescribed medications, or in layman ’s terms, not taking your meds. Fixing this epidemic could not only save billions of dollars but, with around 125,000 deaths a year in the US due to failure to follow doctor’s orders, it could save thousands of lives too.Better lifestyle decisions can solve many of our personal health problems; eating healthily, regular exercise, taking your pills, are all positive behaviors that contribute t...
Source: EyeForPharma - April 5, 2018 Category: Pharmaceuticals Authors: Steve Peretz and Meg Donchak Source Type: news

Roche shares drop after deaths of patients taking Hemlibra
ZURICH (Reuters) - Swiss drugmaker Roche's shares dropped on Wednesday after it told U.S.-based haemophilia advocacy groups that five patients treated with its medicine Hemlibra had died, while maintaining that the therapy was not the cause of the deaths. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche shares drop after reports of deaths of patients taking Hemlibra
ZURICH (Reuters) - Roche shares dropped on Wednesday after U.S.-based National Hemophilia Foundation said Roche's Genentech unit informed it of five deaths of patients treated with its drug Hemlibra. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Tokyo court rejects Shire claim against Roche hemophilia drug
ZURICH (Reuters) - A Tokyo court has ruled that Shire's claim against Swiss drugmaker Roche's new Hemlibra hemophilia medicine should be dismissed, Roche's Japanese subsidiary Chugai said on Wednesday, helping to clear up legal uncertainty over the prospective blockbuster medicine. (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Nanostructures created by UCLA scientists could make gene therapies safer, faster and more affordable
UCLA scientists have developed a new method that utilizes microscopic splinter-like structures called “nanospears” for the targeted delivery of biomolecules such as genes straight to patient cells. These magnetically guided nanostructures could enable gene therapies that are safer, faster and more cost-effective.The research waspublished in the journal ACS Nano by senior author Paul Weiss, UC Presidential Chair and distinguished professor of chemistry and biochemistry, materials science and engineering, and member of theEli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.Gene the...
Source: UCLA Newsroom: Health Sciences - March 15, 2018 Category: Universities & Medical Training Source Type: news

Chance and Prepared Minds Lead from Lab to New Drug Development
A ""failed"" experiment in the lab in 1992 ultimately led to the development of new drugs to treat hemophilia, that were approved by the FDA in 2014. (Source: NIDDK News)
Source: NIDDK News - March 15, 2018 Category: Endocrinology Source Type: news

Sanofi Completes Acquisition of Bioverativ Inc.
Bioverativ Inc. is a fully owned subsidiary of Sanofi Paris (France) - March 8, 2018 -- (Healthcare Sales & Marketing Network) -- Sanofi announced today the successful completion of its acquisition of Bioverativ Inc. ("Bioverativ") for $105 pe... Biopharmaceuticals, Mergers & Acquisitions Sanofi, Bioverativ, hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 8, 2018 Category: Pharmaceuticals Source Type: news

Britain's contaminated blood scandal: ‘I need them to admit they killed our son’
In the 1970s and 80s, 4,689 British haemophiliacs were treated with contaminated blood products. So far, more than half of them have died. The government knew there were risks involved. The patients didn ’t. Will they ever get justice?It has been called the biggest treatment disaster in the history of the NHS, and a “horrific human tragedy”. But Su Gorman, whose husband has endured years of ill health as a result of haemophilia treatment, does not believe this adequately describes Britain’s contaminated blood scandal. As far as she is concerned, it is simply a crime.In the 1970s and 80s, 4,689 haemo...
Source: Guardian Unlimited Science - March 3, 2018 Category: Science Authors: Simon Hattenstone Tags: Health Society & wellbeing Life and style Medical research Science NHS Hepatitis C Aids and HIV Health policy Source Type: news

ICER finds emicizumab offers improvements for haemophilia A
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 1, 2018 Category: Drugs & Pharmacology Source Type: news

Roche says hemophilia drug Hemlibra wins EU approval
ZURICH (Reuters) - Swiss group Roche said on Tuesday the European Commission has approved its drug Hemlibra for people with hemophilia A who have developed resistance to standard treatments. (Source: Reuters: Health)
Source: Reuters: Health - February 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - February 27, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - February 27, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - February 27, 2018 Category: Pharmaceuticals Source Type: news

European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - February 27, 2018 Category: Pharmaceuticals Source Type: news

NIST introduces new CHO peptide library
(National Institute of Standards and Technology (NIST)) LinkedIn: Chinese Hamster Ovary cells, known as CHO, play an important role in modern medicine. NIST's new CHO peptide library will enable better production of treatments for psoriasis, cancer, hemophilia and leukemia. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 22, 2018 Category: International Medicine & Public Health Source Type: news

Cambridge biotech startup seeking to repurpose Vioxx raises $5M
Tremeau Pharmaceuticals, a Cambridge biotech startup that is seeking to repurpose the controversial Merck& Co. arthritis drug Vioxx as a treatment for joint pain caused by hemophilia, has closed its first equity round. Tremeau, which was founded last year, announced Thursday that it has raised $5.2 million in equity financing, although it did not disclose the investors that participated. The six-employee company said the funding would be used to advance the drug — whose generic name is rofecoxib… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 15, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news

Exclusive: Nurses set to lead ‘revolution’ in haemophilia care
Nursing is set to be at the forefront of “revolutionary” changes in haemophilia care, but the profession still carries a burden of “guilt” from the contaminated blood scandal that saw hundreds of NHS patients infected with HIV and hepatitis C, according to a leading specialist nurse. (Source: Nursing Times)
Source: Nursing Times - February 9, 2018 Category: Nursing Source Type: news

Novo Nordisk Launches Rebinyn(R) in the United States for People with Hemophilia B
PLAINSBORO, N.J., Feb. 8, 2018 -- (Healthcare Sales & Marketing Network) -- Novo Nordisk, a global healthcare company, today announced that Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the tr... Biopharmaceuticals, Product Launch Novo Nordisk, Rebinyn, Coagulation Factor IX, Hemophilia B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good results in 2017
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.” (Source: Roche Media News)
Source: Roche Media News - February 1, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good results in 2017
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.” (Source: Roche Investor Update)
Source: Roche Investor Update - February 1, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good results in 2017
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.” (Source: Roche Media News)
Source: Roche Media News - February 1, 2018 Category: Pharmaceuticals Source Type: news

Roche reports good results in 2017
Commenting on the Group ’s results, Roche CEO Severin Schwan said: “In 2017, we made significant progress with good growth in both divisions driven by newly launched medicines and tests. I am particularly pleased with the successful launch of Ocrevus and Hemlibra and important approvals for additional indications for P erjeta, Tecentriq and Alecensa. These medicines bring substantial benefit to patients with serious diseases such as multiple sclerosis, cancer and haemophilia. Based on our strong product portfolio we are well positioned for the future.” (Source: Roche Investor Update)
Source: Roche Investor Update - February 1, 2018 Category: Pharmaceuticals Source Type: news

The Seven Summits —A Hemophilia Triumph
Mountaineer Chris Bombardier: First Person with Hemophilia to Climb the Seven Summits(PRWeb January 31, 2018)Read the full story at http://www.prweb.com/releases/2018/01/prweb15146542.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 31, 2018 Category: Pharmaceuticals Source Type: news

U.S. SEC files suit over possible insider trading on Bioverativ
(Reuters) - The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France's Sanofi in an $11.6 billion deal. (Source: Reuters: Health)
Source: Reuters: Health - January 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche hemophilia drug lowers costs despite high price: ICER
(Reuters) - A costly new Roche Holding AG drug to treat the bleeding disorder hemophilia A could significantly reduce healthcare expenses for certain patients, a draft report from an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - January 27, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A CHMP Backs First-in-Class Drug Emicizumab for Hemophilia A
The CHMP recommended marketing authorization for emicizumab. a first-in-class drug for patients of all ages with hemophilia A with factor VIII inhibitors.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Roche wins EU panel's recommendation for hemophilia drug
ZURICH (Reuters) - A European Union panel on Friday recommended approval of Roche's Hemlibra to treat hemophilia in some patients after the Swiss drugmaker got the green light last year to begin selling the medicine in the United States. (Source: Reuters: Health)
Source: Reuters: Health - January 26, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - January 26, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - January 26, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - January 26, 2018 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with haemophilia A with inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with haemophilia A with factor VIII inhibitors. (Source: Roche Investor Update)
Source: Roche Investor Update - January 26, 2018 Category: Pharmaceuticals Source Type: news

Local fallout from Sanofi ’s $11.6B Bioverativ deal: 3 things to know
Waltham-based Bioverativ, a hemophilia drugmaker that was spun out of Biogen last year, has around 275 employees in the state. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 22, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion
PARIS (Reuters) - French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biotech M & A takes off as Sanofi and Celgene spend $20 billion
LONDON (Reuters) - Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for hemophilia and cancer to their medicine cabinets. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

New drugs recast $10 billion hemophilia market as Sanofi swoops in
LONDON (Reuters) - Sanofi is placing a big bet on the $10 billion-a-year hemophilia market at a testing time, as scientific advances overhaul traditional approaches to treating the rare uncontrolled bleeding disorder. (Source: Reuters: Health)
Source: Reuters: Health - January 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Sanofi, Facing Threat from Generics, Moves to Buy Hemophilia Drug Maker
The $11.6 billion deal for Bioverativ would bolster the French pharmaceutical giant ’ s portfolio as it faces falling sales for its diabetes drug, Lantus. (Source: NYT Health)
Source: NYT Health - January 22, 2018 Category: Consumer Health News Authors: CHAD BRAY Tags: Mergers, Acquisitions and Divestitures Drugs (Pharmaceuticals) Hemophilia Sanofi SA Brandicourt, Olivier Source Type: news

Sanofi to buy Bioverativ, Biogen's hemophilia spinout, for $11.6B
Paris-based Sanofi SA, the state ’s largest biotech employer, said Monday that it will buy hemophilia drugmaker Bioverativ for $11.6 billion, one year after the Waltham company was spun out of Biogen. Sanofi (NYSE: SNY), the parent company of Cambridge-based Sanofi Genzyme, said it will pay $105 per share in cash for Bioverativ (Nasdaq: BIVV), which spun out of Biogen (Nasdaq: BIIB) last January. The price represents a 63 percent premium to Bioverativ’s share price as of Friday. The deal is… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 22, 2018 Category: Pharmaceuticals Authors: Max Stendahl Source Type: news